SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplex, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.
E-mail : compliance@sudarshanpharma.com • **Website :** www.sudarshanpharma.com
Board Line : +91-22-42221111 / 43331111 / 42221116 (100 line) • **CIN :** L51496MH2008PLC184997

Date: 21st May 2026

SPIL/CS/SE/2026-2027/21

To,
The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828
BSE Trading Symbol: SUDARSHAN
ISIN: INE00TV01023

Dear Sir / Madam,

Sub: Revision of Disclosure made by the Company under Paragraph 2.1(f) of the Master Circular compliance with the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 by listed entities.

We refer to our corporate announcement dated May 15, 2026, regarding outcome of the Board Meeting ("**Outcome**"). As part of the mandatory compliance under Paragraph 2.1(f) of the Master Circular for listed entities under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company had attached Annexure A setting out additional information on its Foreign Currency Convertible Bond (FCCB) issue. This Annexure specified a fixed conversion rate of **₹95.93** per US Dollar (USD).

The RBI reference rate prevailing as on the date the subscription agreement between our Company and the bondholders was **₹96.8441** per US Dollar (USD). Hence, the fixed exchange rate has been revised from **₹95.93** to **₹96.8441** per US Dollar (USD).

Pursuant to the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, we enclose the revised **Annexure A** reflecting the updated conversion terms. The BSE and the public (once disseminated) may refer to this Annexure (May 21, 2026) for the additional information under the above Master Circular.

We request you to kindly take the above information on record.

Yours faithfully,

For **Sudarshan Pharma Industries Limited**

Sachin Mehta
Joint Managing Director
DIN: 02211178

Sudarshan Pharma Industries Limited

Encl: Annexure A

SUDARSHAN PHARMA INDUSTRIES LTD
Head Office : 301, Aura Biplex, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.
E-mail : compliance@sudarshanpharma.com • **Website :** www.sudarshanpharma.com
Board Line : +91-22-42221111 / 43331111 / 42221116 (100 line) • **CIN :** L51496MH2008PLC184997

Annexure – A

Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Sr. No.	Particulars	Details
a)	Type of securities proposed to be issued	Foreign Currency Convertible Bonds (FCCBs)
b)	Type of issuance	International offering
c)	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)	Upto USD 20 million in one or more tranches
d)	In case of preferential issue the listed entity shall disclose the following additional details to the stock exchange(s)	Not Applicable
e)	In case of bonus issue the listed entity shall disclose the following additional details to the stock exchange(s)	Not Applicable
f)	In case of issuance of depository receipts (ADR/GDR) or FCCB the listed entity shall disclose following additional details to the stock exchange(s)	
i)	Name of the stock exchange(s) where ADR/GDR/FCCBs are listed (opening – closing status) / proposed to be listed;	--
ii)	Proposed no. of equity shares underlying the ADR/GDR or on conversion of FCCBs;	Considering Issue Size of up to USD 20 million equivalent to INR 193.69 crore, the number of equity shares on conversion would be approximately 6,41,56,409 equity shares of Re. 1/- each of the Company calculated on the basis of Floor Price.
iii)	a) proposed date of allotment; b) tenure, date of maturity; and c) coupon offered, if any of FCCB's	a) FCCBs will be allotted within 60 days from the Issue Closing Date. b) 3 years and 2 months from the date of the FCCBs being fully paid-up. c) 8% per annum
iv)	Issue price of ADR/GDR/FCCBs (in terms of USD and in INR after	Issuance of FCCBs up to USD 20 million

Sudarshan Pharma Industries Limited

	considering conversion rate);	After considering conversion rate of USD 1 = Rs. 96.8441, it would amount to Rs. 193.69 crore
v)	change in terms of FCCBs, if any;	Not Applicable
vi)	details of defaults, if any, by the listed entity in payment of coupon on FCCBs & subsequent updates in relation to the default, including the details of the corrective measures undertaken (if any);	Nil
g)	In case of issuance of debt securities or other non-convertible securities the listed entity shall disclose following additional details to the stock exchange(s)	Not Applicable
h)	Any cancellation or termination of proposal for issuance of securities including reasons thereof.	Not Applicable

For **Sudarshan Pharma Industries Limited**

Sachin Mehta
Joint Managing Director
DIN: 02211178

Sudarshan Pharma Industries Limited